the Celgene-sponsored, pivotal, Phase 3 apact® study evaluating the investigational use of ABRAXANE in combination with gemcitabine following surgical resection (adjuvant treatment) in patients with pancreatic cancer did not achieve the primary endpoint of improvement in disease-free survival, as confirmed by independent radiological review, compared to gemcitabine alone. Overall survival, a secondary endpoint of the study, was improved, reaching nominal statistical significance, with ABRAXANE in combination with gemcitabine compared to gemcitabine alone.
>>982
800症例以上の大規模 臨床試験で、
膵癌で、
celgene
03/12発表です。
the Celgene-sponsored, pivotal, Phase 3 apact® study evaluating the investigational use of ABRAXANE in combination with gemcitabine following surgical resection (adjuvant treatment) in patients with pancreatic cancer did not achieve the primary endpoint of improvement in disease-free survival, as confirmed by independent radiological review, compared to gemcitabine alone. Overall survival, a secondary endpoint of the study, was improved, reaching nominal statistical significance, with ABRAXANE in combination with gemcitabine compared to gemcitabine alone.
引用おわり
プライマリー 未達
で、
セカンダリー OS 達成
→
これcanbasにとっては、やっぱり
ちょっとでも
ほんの少しでも効けば
めちゃくちゃポジティブですね!!
（canbasは、3rdライン
4thライン以降の
ボロボロの膵癌 を対象としておりますますので。。。）